Grace Halsey

Approximately one-third of survey respondents with AUD relapsed within 1 year of stopping. Find a profile here of the experience of recovery from those who are trying.

The observational study found that longer duration of disease conferred a 32% greater risk of obesity and that nonatopic asthma carried at 47% greater risk.

The US FDA expanded approval of remdesivir this week to include pediatric patients aged 28 days and older, the first COVID-19 treatment indicated for this population.

Tirzepatide was associated with reductions in body weight of up to 22.5% over 72 weeks in the global phase 3 registration trial.

As many as 40 000 pharmacies will soon have supplies of Paxlovid while the administration ramps up communications to clinicians and patients on access and use.

USPSTF states low-dose aspirin should be considered for CVD prevention on a case-by-case basis in adults aged 40-59 yrs with a 10% or greater 10-year CVD risk.

More than one-third of survey respondents began drinking before age 15; the heaviest drinkers had double the risk for cirrhosis, CVD, pancreatitis, and neuropathy.

Asthma-COPD overlap and obesity mutually exacerbate each other and an early program of pulmonary rehabilitation shows promise to help both.

Dylan Steen, MD talks about several SuperWIN results that caught him happily by surprise and suggest plenty of room for follow-up research.

A nondescript, postage-paid envelope accompanying an opioid prescription, and patient education on discarding unused tablets are proposed.

Yale headache specialist Christopher Gottschalk, MD, talks about the opportunities to make a marked difference in the quality of patients' lives.

NAFLD is a key risk factor for ASCVD and widely underdiagnosed. This Guideline Topline summarizes new AHA warnings, guidance.

Novavax reports that the various combinations assessed were safe and induced immune responses comparable to stand-alone formulations of both vaccines.

The NDA for daprodustat, a novel investigational agent, is based on data from pivotal ASCEND program clinical trials.

Patients who received a low-dose 3-drug combination pill achieved time at BP target of 64% vs the usual care group result of 43% in a post-hoc analysis of TRIUMPH.

SuperWIN trial findings suggest the future of successful health care depends on harnessing familiar, community- based resources to maintain health and deliver care.

Coprincipal investigator Steen highlights the first-of-its kind study and the findings—local in-store dietitian counseling/feedback, nutrition education, and online shopping savvy improve food choices, health metrics.

Persons with ASCVD who quit smoking could gain 5 more years of life--similar to the outcome of intensive medical treatment while continuing to smoke.

Medical cannabis is already popular with Medicare recipients and many fear insurance coverage will drive up the cost. Find out what else a new survey found.

US patients diagnosed with migraine: 40 million. US headache specialists: 600. Primary care is the answer, according to Christopher Gottschalk, MD.

The FDA clearance for the FitBit algorithm will provide another widely tested tool for patient and clinicians to help identify arrhythmias earlier and avoid severe cardiocerebrovascular events.

The CGRP inhibitor class of injectable migraine preventive agents has a very favorable side effect profile but the drugs do come with some cautions, says Christopher Gottschalk, MD.

In patients with type 2 diabetes and chronic kidney disease with and without history of CVD, finerenone was associated with improved CV and kidney outcomes.

DiabetesWise Pro, created at Stanford University, provides an unbranded, unbiased guide to matching diabetes technology to patient needs, access, and lifestyle.

Opioid refills were reduced by ~40% in the 9 months following an initial prescription for rimegepant among patients with migraine, a new study found.

Initiating diabetes technology of any kind is a big step for patients, but also for a lot of primary care clinicians. If you have concerns, these myths and facts are for you.

The new HF guidelines prioritize primary prevention, revise disease stages to encourage early intervention, and now include SGLT2i as guideline-directed medical therapy.

Dupilumab is the only biologic to show positive, clinically meaningful phase 3 results in adults and adolescents 12 years and older with EoE.

ACC 2022. An EHR alert tailored to prompt clinicians to check guideline-directed medical therapy for individual HF patients was integrated carefully into clinical workflow.

ACC 2022. SODIUM-HF secondary findings, however, showed improvement in NYHA HF class and in QOL in the dietary intervention group.